ClinicalTrials.gg
Sign In

Leukemia, Myeloid, Accelerated Phase clinical trials

The registry lists 318 studies for Leukemia, Myeloid, Accelerated Phase across more than 10 countries. 12 are recruiting or about to start. 20 of them are mainly about Leukemia, Myeloid, Accelerated Phase (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Leukemia, Myeloid, Accelerated Phase studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
217
Terminated
50
Withdrawn
14
Status unknown
13
Recruiting
11
Active, not recruiting
10

Phase

Phase 2
155
Phase 1
99
Phase 3
32
Early Phase 1
1
Phase 4
1

Where

United States
280
France
11
Italy
11
Germany
11
Canada
10
Korea, Republic of
8

Who runs them

Fred Hutchinson Cancer Center (47) · National Cancer Institute (NCI) (20) · M.D. Anderson Cancer Center (19) · City of Hope Medical Center (19) · Memorial Sloan Kettering Cancer Center (16) · Roswell Park Cancer Institute (13) · Case Comprehensive Cancer Center (12) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (9)

What is being tested here

Drugs under test in Leukemia, Myeloid, Accelerated Phase studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Cyclophosphamide2142
Busulfan2131
Ponatinib205
Embibatinib202
Fludarabine1145
Fludarabine phosphate1143
Melphalan1114
Methotrexate1011
Cytarabine109
Clofarabine105

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 open · Antimetabolites 3 open · Alkylating agents 2 open · Calcineurin inhibitors 31 · Corticosteroids 11

Coming up

0phase 3 studies under way
6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Who these studies take

Of the 11 Leukemia, Myeloid, Accelerated Phase studies recruiting now, 3 (27%) set no upper age limit and 6 (55%) stop at 75 or younger. 4 (36%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (18%) take healthy volunteers.

Recruiting studies that take each age, of 11
AgeWomenMen
103 (27%)3 (27%)
189 (82%)9 (82%)
308 (73%)8 (73%)
408 (73%)8 (73%)
508 (73%)8 (73%)
658 (73%)8 (73%)
756 (55%)6 (55%)
854 (36%)4 (36%)

Across all 318 studies, recruiting or not: 45% stop at 75 or younger and 33% at 65; 52% take children; 0% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, Myeloid, Accelerated Phase studies take

Of 28 phase 2 interventional studies under Leukemia, Myeloid, Accelerated Phase, half reached primary completion within 72 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 272 mo39–120 · 28 studies—72 mo39–120 · 26 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 318. Browse all 318 → or search them.